Ixazomib, a second-generation proteasome inhibitor, emerges as a pivotal therapeutic option for managing multiple myeloma. Addressing the needs of multiple myeloma patients, this activity discusses ixazomib’s mechanism of action, indications, and contraindications. The comprehensive discussion extends to ixazomib’s adverse event profile and other critical facets, ensuring the members of an interprofessional team can navigate the complexities inherent in managing multiple myeloma and its associated conditions. The collaborative emphasis throughout underscores the indispensable nature of interprofessional teamwork in managing these intricate hematological conditions and the need to enhance the team’s knowledge and proficiency in leveraging ixazomib to benefit individuals affected by multiple myeloma and its related complexities.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/124789
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABOS - 1.0 Point; Credit Type(s): Accredited CME (ABOS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Ambulatory/Outpatient, Chemical Pathology, General Operative Anesthesia, General Surgery, Geriatric Medicine, Hematology, Hospital Medicine, Internal Medicine, Medical Oncology, Musculoskeletal Oncology